NCNA - NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study | Benzinga
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death
NUC-7738 Alters Ribosome Biogenesis and the Regulation of Genes Critical for Cancer Growth and Survival
SAN DIEGO, April 09, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced two posters being presented today at the American Association of Cancer Research (AACR) Annual Meeting.
Title: Exposing the Heterogeneity of the Lipidome in the TME of Cutaneous Melanoma Following Treatment with NUC-7738 in Combination with anti-PD-1 Therapy
Presentation date and time: April 9, 2024 from 1:30pm-5:00pm PDT
Abstract number: 6222
The tumor microenvironment (TME) is a complex interplay of various cell types, extracellular matrix, signalling molecules and physical factors that collectively influence tumor growth. Lipids play an important role in the TME, contributing to various aspects of cancer progression and therapy resistance. A novel methodology, including imaging mass spectrometry, was developed to investigate the spatial relationship between the lipidome and TME using paired biopsies from patients treated with NUC-7738. NUC-7738 was found to increase polyunsaturated fatty acids within the TME, which is indicative of a shift to a less aggressive cancer type and to decrease monounsaturated fatty acids which are associated with malignant behavior and chemotherapy resistance. In addition, NUC-7738 was shown to reduce lipids associated with protection against cancer cell death and to increase lipids associated with cancer cell death. Multi-modal imaging indicated that this lipid reprogramming is a result of the alteration in enzymes associated with lipid metabolism.
Title: RNA Regulatory Disruption by 3'-dATP: A Novel Approach to Inhibit Ribosome Biogenesis in Cancer
Presentation date and time: April 9, 2024 from 1:30pm-5:00pm PDT
Abstract number: 5650
Ribosome biogenesis is a complex process that plays a pivotal role in protein translation which can become dysregulated in cancer. Thus, ribosome targeting therapies are an attractive treatment modality for anti-cancer medicines. This study investigates the impact of NUC-7738, which generates high intracellular levels of the active anti-cancer metabolite 3'-deoxyadenosine triphosphate (3'-dATP), on the generation of mRNAs and proteins associated with ribosome biogenesis. Data ...